Mental disorders are an urgent health crisis worldwide, especially exacerbated by the pandemic in recent years.


Final Reminder: Low Float (LEXTF) Has 4 Potential Catalysts Including Huge MOU Signing News This Week

(US: LEXTF) - (Canada: LEXT)

January 12th

Greetings Readers,

Mental disorders are an urgent health crisis worldwide, especially exacerbated by the pandemic in recent years.

As per a study by Harvard, the medical cost of mental health conditions is estimated to rise to $6Tn by 2030.

With this rise, doctors/scientists/companies are looking for novel new approaches to combat these issues.

One treatment that has been gaining steam in recent years is the use of psych-e-delics.

The psych-e-delic drugs market is expected to grow at a robust rate and reach a value of $6.33Bn in 2026 from $3.21Bn in 2021 as there is a large unmet need for treatment driving this adoption.

In December 2020, the World Health Organization (WHO) stated that 264 million people suffer from depression.

Growing evidence has suggested that psych-e-delic drugs could treat depression effectively. In a study published in The New England Journal of Medicine, researchers conducted a randomized trial on psi-lo-cybin and found that it is almost as good - if not more effective - than the current antidepressants.

At the end of the six-week trial, all but one of the participants reported a marked improvement in their depressive symptoms - a positive development indeed.

North America is predicted to remain the largest region in the psych-e-delic drugs market due to a surge of clinical trials, massive in-vest-ments, regulatory support, and widespread public awareness.

With this is mind, I've been eyeballing small biotech companies who display tremendous upside potential in taking this fast-growing market to task.

For Wednesday, January 12th, there is only one profile to have at the top of your watch-list:

*Lexston Life Sciences Corp. (LEXTF)*


Lexston Life Sciences Corp. is a Canadian biotechnology company providing cann-a-bis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the psych-e-delic industry with an initial focus on the detection and quantification of psych-e-delic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psych-e-delics in support of burgeoning trials in the field of mental health and wellness.

And right now, the company has 4 potential catalysts going for it:

4 Potential Catalysts For This New Biotech Idea

No. 1 - Monday's Huge MOU Announcement

No. 2 - Company Receives DTC Eligibility

No. 3 - Company Upgrades To The OTCQB

No. 4 - Low Float Profile

But more on that in a second...

Egret Biosciences: The Research & Development Arm of LEXTF

Research & Development is where Egret Biosciences, Lexston’s subsidiary, plays an essential role. However, in reality, it does so much more. Egret is a company that brings together industry experts, organic compounds, and technology to create and advance legal and non-addictive therapeutic treatment alternatives.

Egret’s ApproachEgret is developing an ethical and botanically derived psych-e-delic production pipeline with analytical standards and portable detection technologies to identify and quantify active ingredients. Egret has also leveraged its vast expertise in bioinformatics and molecular biology to develop the first of its kind P.cubensis molecular genetic assay. Egret intends to crowdsource the sampling efforts to characterize the genetic makeup of pharmaceutically interesting Psi-lo-cybe accessions.

Egret’s Analytical Testing Services

Egret prides itself on providing world-class analytics and novel technologies. These are placing Egret on track to improve the efficiency and standardization of commercial cann-a-bis and psych-e-delics production. The team behind Egret has especially honed their skills in rapid turnaround for midstream analyses of cann-a-binoid, terpenoid, and genetics profiles.

Egret also caters to cultivators and breeders with leaf nutrient analyses and plant pathogen detection, such as Hop latent viroid, an up-and-coming major agricultural pest in Cann-a-bis.

Cann-a-bis Genetics

The team at Egret partnered with Lighthouse to deliver the first of its kind, 40’000 marker assay for defensive IP protection, population mapping, and trait-marker association to uncover the genetic basis of its customers’ key traits of interest.

Egret’s also developed a genetic barcode consisting of 23 highly informative markers for use in product traceability through the value chain and for the assessment of diversity in large-scale breeding experiments.

Other genetic services include molecular sexing and chemotyping of plants at the seedling stage. Definitely stay tuned for the results of its first screen of Psi-lo-cybe mush-room accessions from its group of licensed cultivators.

Crispr Tech

CRISPR technology is a simple yet powerful tool for editing genomes. It allows researchers to easily alter DNA sequences and modify gene function. Its many potential applications include correcting genetic defects, treating and preventing the spread of diseases in crops.

Egret’s team has leveraged their extensive expertise in plant genomics and large-scale breeding populations. Thanks to this, it’s uncovered the genetic basis of key traits of interest for commercial cann-a-bis cultivators. The company also entered into a research service agreement with the National Research Council of Canada to develop a pilot study that could improve genetics to create an ideal outdoor cann-a-bis crop for Canadian latitudes.


Egret has partnered with NIRLAB to implement and develop a chemometric algorithm for the rapid detection of drugs, including TH-C and CB-D. This portable device operates in conjunction with a handheld device to provide a non-destructive and immediate means to quantify cann-a-binoids in cure flower. This makes it an ideal tool for law enforcement and the supply chain.

As Egret collects additional spectra, its machine learning algorithm improves the prediction power of the tool. As it continues its foray into other natural products, Egret intends to develop a suite of models for quantifying tryptamines such as psi-lo-cin and DM-T analogs.

After robust operations in Europe for several years, North America is next. The SabIR will be launched in North America shortly with a set of enhanced algorithms explicitly catering to the high cann-a-binoid content of North American cann-a-bis.


To standardize the production of active pharmaceutical ingredients such as cann-a-binoids and tryptamines, chemically and genetically characterized accession will be subject to a plant cell bioreactor. All this will be done by using a technology developed in Israel by Reagenics Research Inc.

Egret will generally callus cultures that form the basis for large-scale API production by leveraging its tissue culture protocols. All while forgoing standard cultivation and potential pitfalls such as pests, environmental variability, and human error.

Egret’s R&D Services

Research & development is Egret’s bread and butter. After all, this is what it primarily does for Lexston Life Sciences.

Egret’s strong background in cann-a-bis genetics has resulted in several publications related to the genetic basis of the chemical expression of cann-a-binoids and terpenes.

But now, it’s leveraging that data to develop custom cann-a-bis cultivars. Egret is constantly improving on their nodal and meristematic tissue cultures. It is also investigating the use of cell cultures to produce secondary metabolites in cann-a-bis and several botanically derived classical psych-e-delics.

Egret’s state-of-the-art R&D lab is focused on developing novel analytical methods for rapid and repeatable chemical and genetic fingerprinting.


While Egret offers terpene analysis using GS-MS through partner labs, it is actively looking to improve the speed and affordability of analytical methods. Egret is developing a significant terpene class assay to detect leading cann-a-bis monoterpenes such as Limonene, Myrcene, Linalool, terpinolene, and sesquiterpene beta-caryophyllene. This assay will offer the ability to classify products based on their anticipated physiological effect at a fraction of the cost of existing methods.


In addition to offering HPLC-based cann-a-binoid profiles, Egret has developed a cann-a-binoid potency method and a portable system that democratizes analytical methods.

It’s also identified several genetic markers associated with cann-a-binoid expression. These markers can be typed in seedlings and significantly improve the selection of important germplasm for large-scale cultivation.


Egret intends to develop chemical and genetic tools for the emerging psych-e-delics industry. These will include analytical methods for common tryptamines, portable detection tools, and genetic assays for each species of interest. Starting with the well-characterized Psi-lo-cybe genus, the egret team has developed a 5000 SNP assay that will be used to understand the chemotypic expression of the pro-drugs psil-o-cybin and biocytin.


Pathogens are a liability to commercial producers due to their cryptic nature. Some even express themselves in later stages of development when an accession has been mass propagated. Egret has developed sampling techniques and molecular assays to detect plant pathogens like viruses, fungi, and bacteria early.

Egret’s Tissue Cultures & Genetic Testing

Egret offers services for tissue culture and genotyping of cann-a-bis strains. These services aim to verify lineage to the cultivator and to provide authenticity to the cann-a-bis consumer.

Egret’s cann-a-bis tissue culture laboratory can produce many contaminant-free elite plants and provide customized plant tissue culture service by producing uniform quality, juvenile vigor, true-to-type plants with its optimized protocols.

This is huge because Tissue Culture is the perfect complement to well-characterized germplasms. The cumulative effort of Egret’s team members with expertise in genetics, chemistry, and pathogen detection has culminated in the development of optimized tissue culture protocols and media suited to a large variety of plants and fungi.

Egret’s system offers its partners the ability to propagate clean and standardized stock to populate their state-of-the-art rooms in a repeatable fashion. Specialized nurseries implementing Egret’s system can also enjoy the ability to swiftly multiply a particular variety and adjust their operations based on the customer demand for specific cultivars.

But beyond this, other advantages of Tissue Culture include reducing the mother room with the large, old plant. This is a high liability situation with little replication to a replicated system on a rack. Each “mother stock” is represented by several young plantlets kept dormant until the stock is ready for multiplication.

Egret works with customers on a case-by-case basis depending on the size and type of operation.

Company Website


And right now, LEXTF has 4 key potential catalysts to know. Check them out:

No. 1 LEXTF Potential Catalyst - Monday's Huge MOU Announcement

Lexston Announces a Memorandum of Understanding with United States Based Panacea Plant Sciences Inc. for Research and Development of Psych-e-delics and Cann-a-bis

Vancouver, British Columbia - TheNewswire - January 10, 2022 - Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (OTC:LEXTF) is pleased to announce the signing of a Memorandum of Understanding (the “MOU”) between its wholly owned subsidiary Egret Bioscience Ltd. (“Egret”) and Panacea Plant Sciences Inc. (“Panacea”), a leading United States biotechnology company focused on developing new therapeutic, cultivation, extraction and isolation techniques for high value natural products such as psych-e-delic-containing lifeforms and cann-a-bis.

Under the terms of the MOU, Panacea and Egret intend to create joint ventures (“JV”) through which they plan to expand the supply chain, reduce the supply cost, and characterize the chemistry and pharmacology of a suite of psych-e-delic compounds using each team’s particular expertise. The goal of the JVs will be to develop cell-based culture systems for the standardized production and formulation of novel psych-e-delic combinations. In addition to assigning intellectual property to the JV, the parties will also assign four percent (4%) of its equity to environmental and indigenous groups associated with the lifeform or compound of interest. The teams recently launched an initial pilot study on allosteric modulators of the serotonin receptor 5HT2A in combination with DM-T, 5-Meo-DM-T, mesc-a-line, LS-D, and psi-lo-cin. This work will identify the mechanisms for the entourage effect of psych-e-delic plant and fungi.

"We are excited to continue our collaboration efforts with Panacea. This agreement is significant for Lexston as it allows us to expand on our expertise in the chemical and genetic analyses of natural products to classical psych-e-delics. Involving the indigenous groups is an important aspect to both companies as it encourages acceptance of our research and can potentially improve many lives,” states Dr. Philippe Henry, Chief Science Officer and Director of Lexston.


Read the full article here.


No. 2 LEXTF Potential Catalyst - Company Receives DTC Eligibility

Lexston Life Sciences Corp. announces DTC Eligibility

Vancouver, British Columbia - TheNewswire - December 15th, 2021 - Lexston Life Sciences Corp. (the "Company" or "Lexston") (CSE:LEXT) (OTC:LEXTF) is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.

DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered "DTC eligible". DTC eligibility is expected to create a seamless process of trading and enhance liquidity of the Company's common shares in the United States over time.

The ability to have Lexston's shares electronically cleared and settled in the United States is far more convenient and reduces the costs incurred in trading shares. With Lexston's shares now traded electronically, existing in-vest-ors benefit from greater liquidity over time and execution speeds, while new in-vest-ors are far less restricted from participating in Lexston's shares. The DTC is the largest securities depository in the world and facilitates electronic settlement of sto-ck certificate transfers in the United States. This electronic method of clearing securities accelerates the settlement process for in-vest-ors and brokers.


Read the full article here.


No. 3 LEXTF Potential Catalyst - Company Upgrades To The OTCQB

Lexston Life Sciences Corp. Announces Upgrade to OTCQB Market in the United States

Vancouver, British Columbia - TheNewswire - November 15, 2021 - Lexston Life Sciences Corp. (CSE:LEXT) (OTC:LEXTF) (the "Company" or "Lexston") is pleased to announce that after successfully completing the application process, the Company has received approval from OTC Markets Group Inc. for its common shares to begin trading on the OTCQB Market ("OTCQB") beginning at market open on November 12, 2021 under the symbol "LEXTF". The Company's common shares will remain listed on the CSE in Canada under the ticker symbol "LEXT".

OTC Markets Group Inc., located in New York, N.Y., operates the world's largest electronic inter-dealer quotation system for broker dealers to trade over 10,000 securities. The OTCQB is a transparent trading platform that offers a cost-effective method for United States in-vest-ors to access Lexston's securities. Lexston's quotation and trading on the OTCQB provides in-vest-ors the opportunity to benefit from streamlined market standards which enhance the availability of information to the general public, enabling greater transparency...


Read the full article here.


No. 4 LEXTF Potential Catalyst - Low Float Profile

According to the OTC Markets' website, LEXTF has a low float.

The website reports this profile to have approximately 36.6Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.


LEXTF Recap - 4 Potential Catalysts For This New Biotech Idea

No. 1 - Monday's Huge MOU Announcement

No. 2 - Company Receives DTC Eligibility

No. 3 - Company Upgrades To The OTCQB

No. 4 - Low Float Profile


Coverage is officially initiated on LEXTF. When you have time, do this:


Get LEXTF on your radar now.


Kai Parker



(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire LLC and Awareness Consulting Network LLC, StockWireNews has been hired for a period beginning on 1/11/22 and ending on 1/12/22 to publicly disseminate information about (LEXTF) via Website, Email and SMS. StockNewsWire LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (LEXTF).